Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.44 |
| ▸ | ADH1A | P07327 | 4/20 | 0.44 |
| ▸ | ADH7 | P40394 | 3/20 | 0.44 |
| ▸ | ADH1C | P00326 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10978329 | 0.87 | ADH1B (0.48) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL13083513 | 0.79 | PRMT3 (0.35) | EPHX1CA1CA2LMNA | |
| SCHEMBL18870730 | 0.78 | ADH1B (0.48) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL12619033 | 0.78 | — | — | |
| SCHEMBL1307052 | 0.76 | — | — | |
| SCHEMBL13511599 | 0.76 | THPO (0.48) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL21558010 | 0.76 | ADH1B (0.39) | ADH1BADH1AADH7ADH1CEPHX1 | |
| Hydrochloric Acid SCHEMBL27219409 | 0.76 | CA1 (0.33) | EPHX1CA1CA2LMNA | |
| SCHEMBL16299187 | 0.74 | TSHR (0.54) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL13986416 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018102769-A1 | TREATMENT OF CANCER | BLUELINK PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ADH1B 3376/4885ADH1A 1910/4885ADH7 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.